Cargando…

Radiosensitivity enhancement by combined treatment of nimotuzumab and celecoxib on nasopharyngeal carcinoma cells

INTRODUCTION: In this study, the radiation-enhancing effects of combined treatment with nimotuzumab, a humanized EGFR-blocking antibody, and celecoxib, a COX-2 selective inhibitor, in human nasopharyngeal carcinoma (NPC) cells were investigated. MATERIALS AND METHODS: 3-(4,5-Dimethylthiazol-2yl)-2,5...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Jianfeng, Yuan, Xiaopeng, Pang, Qingfeng, Zhang, Haowen, Yu, Jiahua, Yang, Bo, Zhou, Leyuan, Zhang, Fuzheng, Liu, Fenju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6052925/
https://www.ncbi.nlm.nih.gov/pubmed/30038488
http://dx.doi.org/10.2147/DDDT.S163595
_version_ 1783340747051761664
author Huang, Jianfeng
Yuan, Xiaopeng
Pang, Qingfeng
Zhang, Haowen
Yu, Jiahua
Yang, Bo
Zhou, Leyuan
Zhang, Fuzheng
Liu, Fenju
author_facet Huang, Jianfeng
Yuan, Xiaopeng
Pang, Qingfeng
Zhang, Haowen
Yu, Jiahua
Yang, Bo
Zhou, Leyuan
Zhang, Fuzheng
Liu, Fenju
author_sort Huang, Jianfeng
collection PubMed
description INTRODUCTION: In this study, the radiation-enhancing effects of combined treatment with nimotuzumab, a humanized EGFR-blocking antibody, and celecoxib, a COX-2 selective inhibitor, in human nasopharyngeal carcinoma (NPC) cells were investigated. MATERIALS AND METHODS: 3-(4,5-Dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide and clonogenic survival assays were done to evaluate the combined cytotoxic and radiosensitizing effects of nimotuzumab or celecoxib or the combination on CNE1 and CNE2 cells. Western blot analysis was performed to identify the effect of nimotuzumab and/or celecoxib with or without irradiation on the cytoplasmic and nuclear EGFR signaling pathways in CNE2 cells. RESULTS: Our results demonstrated that concurrent administration of nimotuzumab and celecoxib cooperatively enhanced the cytotoxicity and radiosensitivity of CNE2 cells but not CNE1 cells. The combination of both drugs with or without irradiation also cooperatively inhibited cytoplasmic and nuclear EGFR signaling pathways in CNE2 cells. CONCLUSION: Our results suggest a promising approach for the treatment of poorly differentiated NPC.
format Online
Article
Text
id pubmed-6052925
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-60529252018-07-23 Radiosensitivity enhancement by combined treatment of nimotuzumab and celecoxib on nasopharyngeal carcinoma cells Huang, Jianfeng Yuan, Xiaopeng Pang, Qingfeng Zhang, Haowen Yu, Jiahua Yang, Bo Zhou, Leyuan Zhang, Fuzheng Liu, Fenju Drug Des Devel Ther Original Research INTRODUCTION: In this study, the radiation-enhancing effects of combined treatment with nimotuzumab, a humanized EGFR-blocking antibody, and celecoxib, a COX-2 selective inhibitor, in human nasopharyngeal carcinoma (NPC) cells were investigated. MATERIALS AND METHODS: 3-(4,5-Dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide and clonogenic survival assays were done to evaluate the combined cytotoxic and radiosensitizing effects of nimotuzumab or celecoxib or the combination on CNE1 and CNE2 cells. Western blot analysis was performed to identify the effect of nimotuzumab and/or celecoxib with or without irradiation on the cytoplasmic and nuclear EGFR signaling pathways in CNE2 cells. RESULTS: Our results demonstrated that concurrent administration of nimotuzumab and celecoxib cooperatively enhanced the cytotoxicity and radiosensitivity of CNE2 cells but not CNE1 cells. The combination of both drugs with or without irradiation also cooperatively inhibited cytoplasmic and nuclear EGFR signaling pathways in CNE2 cells. CONCLUSION: Our results suggest a promising approach for the treatment of poorly differentiated NPC. Dove Medical Press 2018-07-16 /pmc/articles/PMC6052925/ /pubmed/30038488 http://dx.doi.org/10.2147/DDDT.S163595 Text en © 2018 Huang et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Huang, Jianfeng
Yuan, Xiaopeng
Pang, Qingfeng
Zhang, Haowen
Yu, Jiahua
Yang, Bo
Zhou, Leyuan
Zhang, Fuzheng
Liu, Fenju
Radiosensitivity enhancement by combined treatment of nimotuzumab and celecoxib on nasopharyngeal carcinoma cells
title Radiosensitivity enhancement by combined treatment of nimotuzumab and celecoxib on nasopharyngeal carcinoma cells
title_full Radiosensitivity enhancement by combined treatment of nimotuzumab and celecoxib on nasopharyngeal carcinoma cells
title_fullStr Radiosensitivity enhancement by combined treatment of nimotuzumab and celecoxib on nasopharyngeal carcinoma cells
title_full_unstemmed Radiosensitivity enhancement by combined treatment of nimotuzumab and celecoxib on nasopharyngeal carcinoma cells
title_short Radiosensitivity enhancement by combined treatment of nimotuzumab and celecoxib on nasopharyngeal carcinoma cells
title_sort radiosensitivity enhancement by combined treatment of nimotuzumab and celecoxib on nasopharyngeal carcinoma cells
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6052925/
https://www.ncbi.nlm.nih.gov/pubmed/30038488
http://dx.doi.org/10.2147/DDDT.S163595
work_keys_str_mv AT huangjianfeng radiosensitivityenhancementbycombinedtreatmentofnimotuzumabandcelecoxibonnasopharyngealcarcinomacells
AT yuanxiaopeng radiosensitivityenhancementbycombinedtreatmentofnimotuzumabandcelecoxibonnasopharyngealcarcinomacells
AT pangqingfeng radiosensitivityenhancementbycombinedtreatmentofnimotuzumabandcelecoxibonnasopharyngealcarcinomacells
AT zhanghaowen radiosensitivityenhancementbycombinedtreatmentofnimotuzumabandcelecoxibonnasopharyngealcarcinomacells
AT yujiahua radiosensitivityenhancementbycombinedtreatmentofnimotuzumabandcelecoxibonnasopharyngealcarcinomacells
AT yangbo radiosensitivityenhancementbycombinedtreatmentofnimotuzumabandcelecoxibonnasopharyngealcarcinomacells
AT zhouleyuan radiosensitivityenhancementbycombinedtreatmentofnimotuzumabandcelecoxibonnasopharyngealcarcinomacells
AT zhangfuzheng radiosensitivityenhancementbycombinedtreatmentofnimotuzumabandcelecoxibonnasopharyngealcarcinomacells
AT liufenju radiosensitivityenhancementbycombinedtreatmentofnimotuzumabandcelecoxibonnasopharyngealcarcinomacells